At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our 35,000 employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We're looking for people who are determined to make life better for people around the world.

People with migraine and cluster headache journey in and out of relentless cycles of pain and disruption to their life. Even though we may not recognize it, each of us most likely knows someone living with migraine as it affects approximately 1 billion people across the globe. Until 2018, the migraine market had not seen significant innovation in more than two decades. However, between 2018 and 2022, a number of new products for acute and prevention treatment have and/or will enter the market. Lilly is positioned to lead with Emgality and REYVOW.

Emgality (galcanezumab) is a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP) and was approved by the FDA in September 2018 for the preventive treatment of migraine in adults and in June 2019 for the treatment of episodic cluster headache in adults. Emgality was also approved in Europe in November 2018 for the prophylaxis of migraine in adults who have at least four migraine days per month. Most major markets have launched the migraine prevention indication giving patients more good days, and chance for a richer life. As the NBRx CGRP antibody leader in the US market and an incredibly strong 2021 launch in Japan, Emgality is well positioned to become the global mAb market leader in a competitive marketplace giving people a chance of migraine freedom.

REYVOW (lasmiditan) is an oral treatment that binds to 5-HT1F receptors with high affinity and is approved by the FDA for the acute treatment of migraine, with or without aura, in adults. The Q1 2020 US launch and the upcoming OUS approvals (specifically Japan) are significant as REYVOW represents one of the first new classes of acute migraine treatments to enter the market in more than two decades. While REYVOW's ability to deliver efficacy (pain freedom; fast and complete elimination of pain) is at the center of the brand's value proposition, it is critical that we connect across customer groups to quickly drive confidence and experience in the face of aggressive competition.

Position Description:

The Associate Director, Launch Readiness & Affiliate Engagement, Global Marketing Migraine (Emgaltiy & REYVOW) will focus on the NBU integration strategy (Migraine & Alzheimer's), lifecycle planning for Emgality, affiliate engagement strategy & shared learnings, launch readiness preparations and congress planning. This person will also be responsible for business plan, OPEX management and be the main contact for the marketing agency.

Key Objectives/Deliverables:

• Responsible for the NBU integration strategy between the Migraine & Alzheimer's brands amidst the evolving competitive landscape
• Responsible for Emgality lifecycle planning for future indications based in scientific rationale
• Lead launch readiness in the IBU for REYVOW and affiliate engagement across the globe
• Lead marketing agency management
• Collaborate with migraine platform associate to provide input into TA foundational strategy, integration of competitive intelligence insights and congress strategy
• Support Product Director in delivering annual business plan

Basic Qualifications:

• Bachelor's Degree
• Experience in Global and/or Affiliate Marketing
• Qualified candidates must be legally authorized to be employed in the United States. Lilly does not anticipate providing sponsorship for employment visa status (e.g., H-1B or TN status) for this employment position.

Additional Skills/Preferences:

• A TEAM LILLY mindset with a focus on include, innovate, accelerate and deliver
• Demonstrated track record of strong strategic thinking and problem solving
• Proven cross-functional partnering capabilities, particularly with Medical, Regulatory, Health outcomes and Legal
• Experience in Migraine and/or Neuroscience
• Deep understanding, application and execution of customer insight to brand strategy
• Experience launching brands in new indications in markets new to Eli Lilly

• Proven ability to effectively lead and challenge conventional wisdom at all levels to produce innovative, customer-oriented solutions
• Seeks out and acts on feedback, strong self-awareness and EQ
• MBA
• Desire to have fun at work!

Additional Information:

• Lilly is an EEO/Affirmative Action Employer and does not discriminate on the basis of age, race, color, religion, gender, sexual orientation, gender identity, gender expression, national origin, protected veteran status, disability or any other legally protected status.

Travel Percentage:

• 0-10%

Eli Lilly and Company, Lilly USA, LLC and our wholly owned subsidiaries (collectively "Lilly") are committed to help individuals with disabilities to participate in the workforce and ensure equal opportunity to compete for jobs. If you require an accommodation to submit a resume for positions at Lilly, please email Lilly Human Resources ( [email protected] ) for further assistance. Please note This email address is intended for use only to request an accommodation as part of the application process. Any other correspondence will not receive a response.

Lilly is an EEO/Affirmative Action Employer and does not discriminate on the basis of age, race, color, religion, gender, sexual orientation, gender identity, gender expression, national origin, protected veteran status, disability or any other legally protected status.

As a condition of employment with Eli Lilly and Company and its subsidiaries in the United States and Puerto Rico, you must be fully COVID-19 vaccinated and provide proof of vaccination satisfactory to the company (subject to applicable law).